ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lutetium-177

Also written as “[177Lu]Lu-NeoB”, “[177Lu]Lu-PSMA-617” and “Lutetium[177Lu] Oxodotreotide Injection”.

In Novartis’s pipeline, Radioligand therapy target HER2. Its studies are mostly in Prostatic Neoplasms · Breast Neoplasms · Neuroendocrine Tumors · Glioblastoma · Carcinoma, Non-Small-Cell Lung, led by 11 companies.

Drug pageLutetium-177: every studyMany companies study it; this page follows only the 24 they lead. All 41 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 16, 202024 company-led studies, 19 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis107 open or runningphase 2since Dec 16, 2020Dec 16, 2020Dec 30, 2026phase 1 · NCT05870579
Sinotau Pharmaceutical Groupits history only32 open or runningphase 3since Jul 5, 2022Jul 5, 2022Jun 1, 2027phase 3 · NCT06398444
Braccoits history only21 open or runningphase 2since May 20, 2022May 20, 2022none ahead
Sichuan Biokin Pharmaceuticalits history only22 open or runningphase 1since Nov 14, 2025Nov 14, 2025Dec 2027phase 1 · NCT07232407
Affibodyits history only11 open or runningphase 1since Jun 23, 2025Jun 23, 2025Jun 1, 2027phase 1 · NCT07081555
Alpha-9 Oncology USAits history only11 open or runningphase 1since Jun 9, 2026Jun 9, 2026Dec 2028phase 1 · NCT07661641
Cellbionits history only11 open or runningphase 1since Nov 14, 2025Nov 14, 2025Apr 2029phase 1 · NCT07244393
FutureChemits history only11 open or runningphase 2since Jun 10, 2022Jun 10, 2022none ahead
Jiangsu HengRui Medicineits history only11 open or runningphase 3since May 22, 2023May 22, 2023Dec 2026phase 3 · NCT05884255
Philogenits history only11 open or runningphase 1since Oct 10, 2024Oct 10, 2024May 31, 2028phase 1 · NCT06640413

Also a collaborator on its studies: Merck, PSI CRO, Baili-Bio (Chengdu) Pharmaceutical and Medpace.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2020First study: phase 2 study in PheochromocytomaFirst studyNCT04711135 · 11 enrolled · United States, France, Poland and more
  2. Nov 7, 2022Phase 2 study in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT05670106 · 62 enrolled · China
  3. Dec 12, 2022Phase 2 study in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT05658003 · 63 enrolled · China
  4. Jan 17, 2023Phase 1 study in GlioblastomaNCT05739942 · 42 enrolled · United States, France, Germany and more
  5. May 8, 2023Phase 1 study in Breast NeoplasmsNCT05870579 · 28 enrolled · United States, China, France and more
  6. Jan 17, 2024Phase 2 study in Breast NeoplasmsNCT06247995 · 20 enrolled · United States, Australia, Canada and more
  7. Mar 4, 2024Phase 1 study in Metastatic Neuroendocrine Prostate CancerNCT06379217 · 31 enrolled · United States, France, Germany and more
  8. Aug 16, 2024Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06562192 · 162 planned · United States, Belgium, Canada and more
  9. Feb 25, 2025Phase 2 study in Prostatic NeoplasmsNCT06881823
  10. Jun 15, 2026Phase 1 study in Breast NeoplasmsNCT07660055 · 156 planned · United States, Australia, Canada and more
  11. Nov 17, 2026Phase 1 study terminatedStudy stoppedNCT06379217 · “Sponsor decision and not a consequence of any safety concerns.”

Ahead

  1. Dec 30, 2026Primary completion: phase 1 study in Breast NeoplasmsNCT05870579
  2. Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06247995
  3. Aug 10, 2027Primary completion: phase 1 study in GlioblastomaNCT05739942
  4. Jan 15, 2031Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06562192

TargetBeta

“Radioligand therapy target HER2”the company's pipeline, read by Claude · source
“Radioligand therapy target FAP”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Gallium-68Philogenphase 317

Studies

All 10 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07660055Breast Neoplasms · United States, Australia, Canada and more1RecruitingMay 24, 2032156
NCT06881823Prostatic Neoplasms2WithdrawnMar 31, 20300
NCT06562192Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more1RecruitingJan 15, 2031162
NCT06379217Metastatic Neuroendocrine Prostate Cancer · United States, France, Germany and more1TerminatedOct 16, 202631
NCT06247995Breast Neoplasms · United States, Australia, Canada and more2Active, not recruitingApr 14, 202720
NCT05870579Breast Neoplasms · United States, China, France and more1Active, not recruitingDec 30, 202628
NCT05739942Glioblastoma · United States, France, Germany and more1Active, not recruitingAug 10, 202742
NCT05658003Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China2Active, not recruitingDec 2, 202463
NCT05670106Metastatic Castration-Resistant Prostate Cancer (mCRPC) · China2CompletedMay 17, 202462
NCT04711135Pheochromocytoma · United States, France, Poland and more2Active, not recruitingMar 12, 202411

How it is read

Names in the registry

  • “[177Lu]Lu-NeoB”, 4 entries
  • “[177Lu]Lu-PSMA-617”, 3 entries
  • “Lutetium[177Lu] Oxodotreotide Injection”, 2 entries
  • “Lutetium [177Lu] BL-ARC001”, 2 entries
  • “[177Lu]Lu-ABY-271”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.